Table 1.

Cox Proportional Hazards Models

	Overall Survival			Recurrence-Free Survival
	Hazard Ratio	95% CI	P	Hazard Ratio	95% CI	P
	All Patients
Axillary Lymph Node Disease
Axillary pCR	Ref			Ref
Axillary Residual Disease	3.02	(2.14, 4.27)	<0.001	3.10	(2.31, 4.15)	<0.001
Age
≤ 50	Ref			Ref
> 50	1.16	(0.95, 1.43)	0.15	0.92	(0.76, 1.10)	0.35
Race
Other	Ref			Ref
African American	1.3	(0.98, 1.72)	0.07	1.18	(0.92, 1.52)	0.19
Breast Cancer Subtype
HR+/HER2−	Ref			Ref
HR+/HER2+	1.07	(0.76, 1.50)	0.70	1.09	(0.81, 1.47)	0.57
HR−/HER2−	1.25	(0.86, 1.81)	0.23	1	(0.72, 1.40)	0.99
HR−/HER2+	0.7	(0.44, 1.10)	0.12	0.82	(0.55, 1.21)	0.31
Clinical T Stage
T0–T2	Ref			Ref
T3–T4	1.72	(1.39, 2.12)	<0.001	1.65	(1.37, 1.99)	<0.001
Pathological T Stage
T0	Ref			Ref
T1–T4	2.15	(1.53, 3.02)	<0.001	1.91	(1.43, 2.55)	<0.001
Nuclear grade
I or II	Ref			Ref
III	1.63	(1.25, 2.11)	<0.001	1.47	(1.18, 1.83)	0.001
Adjuvant Treatment
No Adj XRT/No Adj ET	Ref			Ref
Adj XRT/No Adj ET	0.43	(0.31, 0.61)	<0.001	0.37	(0.28, 0.51)	<0.001
No Adj XRT/Adj ET	0.30	(0.17, 0.53)	<0.001	0.25	(0.15, 0.41)	<0.001
Adj XRT/Adj ET	0.22	(0.15, 0.32)	<0.001	0.18	(0.12, 0.24)	<0.001
Patients with HER2-Overexpressing Breast Cancer
Axillary Lymph Node Disease
Axillary pCR	Ref			Ref
Residual Axillary Disease	3.49	(1.98, 6.16)	<0.001	4.51	(2.75, 7.39)	<0.001
Clinical T Stage
T0–T2	Ref			Ref
T3–T4	1.71	(1.12, 2.62)	0.01	1.42	(0.98, 2.06)	0.06
HER2-Targeted Therapy
No	Ref			Ref
Yes	0.58	(0.33, 1.00)	0.05	0.72	(0.47, 1.12)	0.15
Patients with HER2-Overexpressing Breast Cancer Receiving HER2-Targeted Therapy
Axillary Lymph Node Disease
Axillary pCR	Ref			Ref
Residual Axillary Disease	1.24	(0.39, 3.99)	0.70	2.34	(0.96, 5.71)	0.06
Clinical T Stage
T0–T2	Ref			Ref
T3–T4	4.32	(1.22, 15.29)	0.02	1.33	(0.63, 2.81)	0.45
Pathological T Stage
T0	Ref			Ref
T1–T4	6.61	(1.58, 27.66)	0.01	3.82	(1.42, 10.31)	0.008
HR Status
Negative	Ref			Ref
Positive	0.37	(0.13, 1.07)	0.07	0.30	(0.13, 0.68)	0.004

Adj = Adjuvant

XRT = Radiation Therapy

ET = Endocrine Therapy